Taking the fight to inflammatory disease: InflaRx’s first-in-class C5a/C5aR signaling pathway strategy
- Author
- Labiotech
- Published
- Fri 18 Jul 2025
- Episode Link
- None
Inflammatory diseases involve excessive or ongoing inflammation that damages tissues and affects many different human systems, including digestion, immunity, circulation, breathing, and the nervous system. The demand for anti-inflammatory treatments is growing quickly and is tipped to top a quarter of a trillion dollars within the decade as cases increase and new approaches to address inflammation emerge.
This week, I had the chance to talk to Niels Riedemann, CEO and Founder of InflaRx, about his company’s first-in-class approach to fighting inflammation, and what the future might hold for his “pipeline in a product”.
01:26 Introducing Niels Riedemann
04:28 InflaRx and its mission
06:37 The competitive landscape in anti-inflammatory therapeutics
07:21 The market for anti-inflammatories
08:40 The challenge of taking a drug from R&D to commercialization
11:06 The science behind the C5a and C5aR approach
14:37 Why is InflaRx the first to focus on these selective inhibitors?
19:18 The importance of the MAC formation
21:05 InflaRx and its disease targets
25:46 Applications beyond anti-inflammatories
27:50 Lessons learned from the clinic
29:54 Growth forecasts for InflaRx
31:48 Different approaches to addressing inflammation
33:51 The role of academia in breakthrough therapies
36:11 Beyond Europe and North America, addressing the global demand for therapeutics
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
